Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort-Reference-Cited by-同舟云学术

Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort

Published:2018-11-21 Issue:2 Volume:20 Page:137-146
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Modica S¹²^ORCID,Rossetti B¹^ORCID,Lombardi F³,Lagi F⁴,Maffeo M¹²,D'Autilia R⁵,Pecorari M⁶,Vicenti I²,Bruzzone B⁷,Magnani G⁸,Paolucci S⁹,Francisci D¹⁰,Penco G¹¹,Sacchini D¹²,Zazzi M²,De Luca A¹²,Di Biagio A¹³^ORCID

Affiliation:

1. Infectious Diseases Unit; Siena University Hospital; Siena Italy

2. Department of Medical Biotechnologies; University of Siena; Siena Italy

3. Institute of Clinical Infectious Diseases; Catholic University of the Sacred Heart; Rome Italy

4. Department of Experimental and Clinical Medicine; University of Florence; Florence Italy

5. Department of Mathematics; University of Roma Tre; Rome Italy

6. Unit of Microbiology and Virology; Modena University Hospital; Modena Italy

7. Hygiene Unit; Policlinico San Martino Hospital; Genoa Italy

8. Department of Infectious Diseases; S. Maria Nuova IRCCS Hospital; Reggio Emilia Italy

9. Molecular Virology Unit; Microbiology and Virology Department; IRCCS San Matteo Hospital Foundation; Pavia Italy

10. Infectious Diseases Clinic; Perugia University Hospital; Perugia Italy

11. Department of Infectious Diseases; Galliera Hospital; Genoa Italy

12. Clinic of Infectious Diseases; ‘Guglielmo da Saliceto' Hospital; Piacenza Italy

13. Infectious Diseases Clinic; Policlinico San Martino Hospital; Genoa Italy

Funder

ViiV Healthcare

Gilead Sciences

Janssen

Hologic

Meso Scale Diagnostics

Bristol-Myers Squibb

Siemens Healthineers

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hiv.12692/fullpdf

Reference36 articles.

1. HIV drug resistance and the advent of integrase inhibitors;Quashie;Curr Infect Dis Rep,2013

2. Antiretroviral drugs for treatment and prevention of hiv infection in adults;Günthard;JAMA,2016

3. Panel on antiretroviral guidelines for adults and adolescents http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

4. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells;Hazuda;Science,2000

5. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials;Eron;Lancet Infect Dis,2013

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir;Medicine;2023-10-06

2. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings;Journal of Antimicrobial Chemotherapy;2023-04-24

3. Prevalence of Transmitted Drug Resistance among HIV-1 Patients in the Aegean Region: Results from the Western Part of Turkey;Current HIV Research;2023-03

4. Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens;Frontiers in Microbiology;2022-12-12

5. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1;Current HIV Research;2022-03